News
FDA Expands Approval of Pfizer’s TALZENNA Plus XTANDI for Metastatic Prostate Cancer
The FDA’s expanded approval, supported by Phase 3 TALAPRO-3 results, brings Pfizer’s TALZENNA plus XTANDI combination to an earlier treatment setting for men with HRR-mutated metastatic prostate cancer.
imphoenix82
- October 28, 2026
- 0 Comments
- 70 Views
-
